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2. Introduction 
 
2.1 Hepatitis 
 
Hepatitis (from Greek: hepar = liver and itis = inflammation) implies a systemic illness, in 
which the liver is predominantly affected. The hepatitis is associated with changes of 
clinical, biochemical and serological parameters and inflammatory cells in the liver tis-
sue. Viruses, bacteria, parasites, drugs and alcohol can cause this disease. The viral 
hepatitis is one of the most common infectious diseases worldwide, caused by viruses 
A-E. Concerning the progression a differentiation between acute and chronic hepatitis is 
possible.1 
 
2.2 Course of viral hepatitis 
 
2.2.1 Acute viral hepatitis 
 
Clinically, there is no possibility to differentiate between acute infections with the hepati-
tis viruses A-E. Concerning the gentlest form of acute hepatitis, patients show no char-
acteristic inflammation symptoms at all, therefore the infection can only be verified by 
detection of increased transaminases in the blood. The incubation time varies between 
2-26 weeks, depending on virus type and is free of symptoms. An uncharacteristic, flu-
like prodromal stadium for 3-4 days follows. In this stadium the patients suffer from fa-
tigue, anorexia, sickness, vomiting, abdominal pain and pression. The prodromal sta-
dium can be followed by a 1-4 weeks lasting icteric stadium, characterized by darkened 
urine, decolorized feces and pruritus.1 
The progression of an acute hepatitis has to be monitored to avoid the development of a 
fulminant hepatitis which occurs for example in 0.5-1 % for the hepatitis C.1  
 
2.2.2 Chronic viral hepatitis 
 
The majority of the acute viral hepatitides heals without further intricacies. However, an 
infection with the hepatitis viruses B, C and D may lead to a chronic course, whereas a 
chronic hepatitis is characterized by an inflammation of the liver lasting longer than 6 
months and histopathological changes of the liver. Frequently, the patients are free from 
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symptoms or show unspecific ailments like abnormal fatigue and malaise. Normally, de-
tection of increased transaminases is the only noticeable proof for a chronic hepatitis.1 
The course of the disease ranges from an inflammation that stays below the surface of 
clinical detection to a rapidly proceeding hepatitis passing into cirrhosis which may lead 
to hepatocellular carcinoma.1  
 
2.3 Hepatitis C 
 
Hepatitis C (HC) is an inflammation of the liver caused by the hepatitis C virus (HCV) 
and is the major cause of liver transplantation in Europe.2 It is estimated that 3 % of the 
world’s population, more than 170 million people, are infected with HCV3 (Germany: 
400,000-500,000)4. The transmission of the disease predominantly occurs parenteral by 
intravenous drug abuse, sexual intercourse, piercing, tattoos and dialysis.5 With the ad-
vent of routine blood screening for HCV antibodies (since 1991 in most countries) the 
risk of infection by the use of blood products has been minimized.2  
The incubation time of HC lasts from 15 to 150 days whereas approximately 25 % of the 
infections heal without further complications.1 The acute infection is associated with a 
symptomatic course (chapter 1.2.1) in 25 % only, for which reason the HC is often diag-
nosed in a late chronic stadium of the illness first.1  
An estimated 50-80 % of the acute infections do not heal and result in a chronic HC with 
a spontaneous elimination of the virus in exceptional cases only. The chronic HC is not 
caused by the direct destruction of hepatic cells by the virus, it results from an immune 
response that is large enough to induce hepatic cell destruction and fibrosis but not 
enough to eradicate the virus.2 After 20-30 years of chronic HC infection a fibrosis de-
velops in 50 %, cirrhosis in 20 % of the patients. The patients with HCV induced cirrho-
sis do have a risk of developing a hepatocellular carcinoma of 1-4 % per year. An infec-
tion with HC causes no immunity which means a reinfection is possible at any time.1 
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2.4 Diagnosis of hepatitis C  
 
Initially the transaminases are clearly increased in 80 % of the patients which is a first 
hint for an acute hepatitis whereas 66 % of chronically infected patients show increased 
transaminases as well.1 
Serologically, on one hand the HCV infection is diagnosed by detection of specific anti-
bodies which is possible 6-8 weeks after infection. On the other hand an identification of 
the viral RNA is necessary after a positive HCV antibody diagnosis since HCV antibod-
ies are detectable up to 20 years after healing. If no HCV antibody is found, determina-
tion of the viral RNA is necessary to exclude acute infection.1 
Currently, an immunoblot assay is used for the identification of HCV antibodies and po-
lymerase chain reaction for the detection of the viral RNA.6  
 
2.5 Therapy of hepatitis C 
 
Almost all patients with acute hepatitis C rapidly become HCV RNA negative on pegy-
lated interferon-α (PEG IFN-α) therapy.7 The current standard of treatment for chronic 
hepatitis C is the combination of ribavirin and PEG INF-α (figure 1) in which a large 
molecule of polyethylene glycol (PEG) is covalently attached to recombinant IFN-α, 
leading to longer half-life, better pharmacokinetic profile and better rate of virological 
response.  
O
HOH2C
HO OH
N
N
N
O
NH2
H
O
O
Interferon-α
n
Ribavirin PEG interferon-α  
Figure 1: Structure of ribavirin and PEG interferon-α, average molecular weight 19241.10 g/mol (inter-
feron-α: polypeptide consisting of 166 amino acids). 
 
This combination of therapeutic agents yields overall sustained virologic response (SVR) 
rates of 54-56 % in which duration of the treatment varies from 24 to 48 weeks, depend-
ing on the viral genotype.7 A transient response with relapse occurs in 10-25 % of pa-
tients despite optimal regimens whereas the cause of relapse remains unknown.7 If the 
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transaminases stay normal and the viral RNA is beyond detection for 6 months after end 
of treatment an ongoing success of therapy is anticipated.5 Furthermore, liver transplan-
tation is the primary treatment option for patients with decompensated cirrhosis or hepa-
tocellar carcinoma.2; 8 
Concerning PEG IFN-α the antiviral activity does not result from targeting the virus di-
rectly or from affecting the viral replication cycle. Rather, it induces an IFN-stimulated 
non-virus-specific antiviral state within the host cells and stimulates the adaptive and 
innate immune system. Ribavirin, a guanosine analogue, possesses broad antiviral ac-
tivity. The exact mode of action of ribavirin remains unclear so far. An attractive hy-
pothesis to explain the effects is a lethal mutagenesis of HCV under the treatment of 
ribavirin.7  
Due to the genetic heterogeneity of the virus, caused by the high replicative activity, a 
vaccine against hepatitis C is not available yet. However the situation is quite promising 
today since eradication of the virus occurs in 20-50 % of the patients, associated with 
specific immune responses, and clear evidence for some natural immunity has emerged 
recently in humans and chimpanzees. Therefore many therapeutic vaccine trials are 
planned or are already in progress but little information is available about their efficacy 
at present.9 
Due to the severe influenza-like side effects and the limited virologic response much 
attention is now being focused on the development of new drugs like HCV protease, po-
lymerase, helicase and other specific inhibitors.10 
 
2.6 The hepatitis C virus 
 
The hepatitis C virus is a positive stranded RNA virus classified in the Hepacivirus ge-
nus within the Flaviviridae family. HCV was first described in 1975 as non-A, non-B 
hepatitis virus and identified in 1989. Despite great progress made in the past years the 
structure of HCV remains to be elucidated. Derived from related alphaviruses and 
flaviviruses it is speculated that the virion is composed of a nucleocapsid containing the 
genomic RNA and a double-layer lipid envelope. Furthermore, the surface glycoproteins 
E1 and E2 are anchored to the lipid bilayer. A schematic structure of the viral particle is 
given in figure 2. The HCV genome consists of 9.6 kilobases and encodes a polyprotein 
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precursor of about 3000 amino acids which is processed by cellular and viral proteases 
into the mature structural (Core, E1, E2) and non-structural proteins (p7, NS2, NS3, 
NS4A, NS4B, NS5A and NS5B). Figure 3 shows the HCV polyprotein including the bio-
logical function of the individual proteins.11 
 
 
Figure 2: Schematic structure of the hepatitis C virus. 
 
 
Figure 3: Hepatitis C virus proteins including their biological functions (taken from reference 11).  
 
HCV isolates can be classified into 6 major genotypes and about 50 subtypes whereas 
the genotypes differ in their nucleotide sequence by 30-35 % and the subtypes by 20-25 
%. This genetic heterogeneity of the population of HCV genomes (quasispecies) coex-
isting in an infected individual hampers the treatment of HC (see 1.5).11; 12     
The lifecycle of HCV can be separated into 6 major steps (figure 4): Virus binding and 
internalization, release and uncoating, translation and polyprotein processing, RNA rep-
lication, packaging and assembly and virion release. Whereas currently little is known 
about the packaging, assembly and virion release.11 In principle, each of the mentioned 
steps is a target for treatment of HCV. 
E2 glycoprotein 
E1 glycoprotein 
nucleocapsid 
positive stranded RNA 
envelope 
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Figure 4: Lifecycle of hepatitis C virus: Virus binding and internalization (a), release and uncoating (b), 
translation and polyprotein processing (c), RNA replication (d), packaging and assembly (e), virion release 
(f) (taken from reference 11).  
 
The targets for anti HCV therapy – presently used or discussed – are presented in the 
following. 
 
2.7 Potential targets for the treatment of hepatitis C 
 
2.7.1 The p7 protein 
 
It has been suggested that the p7 protein could form ion channels in the endoplasmic 
reticulum which might be necessary for HCV replication. This makes it a potential target 
for antiviral therapy. Presently some long-alkyl-chain iminosugar derivatives are under 
clinical evaluation (figure 5). These are derived from the glucose analogue deoxynojiri-
mycin (DNJ) or the galactose analogue deoxygalactonojirimycin (DGJ).13; 14   
 
N
OH
OHCH3HO
(CH2)6 OC2H5
N-7-oxanonyl-6-methyl-DGJ
N
OH
OHCH3HO
(CH2)8 OCH3
N-9-oxadecyl-6-methyl-DGJ
N
HO
HO
OH
OH
(CH2)8 CH3
N-nonyl-DNJ  
Figure 5: Structures of long-alkyl-chain iminosugars. 
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2.7.2 The NS2 auto-protease 
 
The NS2 auto-protease cleaves the non-structural proteins NS2 and NS3. No NS2 in-
hibitors have been developed so far.14 
 
2.7.3 The NS3 protease / helicase 
 
On one hand, NS3 cleaves together with its cofactor NS4A the polyprotein at four junc-
tions. On the other hand, NS3 holds the helicase needed to unwind the viral genomic 
RNA during replication. Several potential inhibitors targeting protease activity are cur-
rently at the preclinical or early clinical stage. These compounds are oligopeptides re-
cently developed.15 The structure of VX-950 (Telaprevir©, Vertex) is exemplarily shown 
in figure 6. By contrast no compound for the inhibition of the NS3 helicase has reached 
clinical development yet.10; 14 
N
N
O
H
N
O
N
H
O
N
O
H
N
O
O
H
N
 
Figure 6: Structure of VX-950. 
 
2.7.4 The NS5A phosphoprotein 
 
The NS5A phosphoprotein plays a role in viral replication. Its exact function and three-
dimensional structure is still unknown.14 Nonetheless, recently achieved results suggest 
several substituted pteridines to inhibit HCV replication by interfering with NS5A. The 
structure of one of these compounds is shown in figure 7. Their exact mechanism of ac-
tion is presently further elucidated.16 
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N
N
N Br
F
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N
 
Figure 7: Substituted pteridine, an inhibitor of HCV replication.  
 
2.7.5 The NS5B RNA-dependent RNA polymerase 
 
The NS5B protein contains the RNA-dependent RNA polymerase (RdRp) which is the 
catalytic component necessary for the HCV replication process. This enzyme synthe-
sizes RNA using an RNA template. For prevention of the RdRp activity several potential 
nucleoside as well as non-nucleoside inhibitors were found, currently at the preclinical or 
early clinical developmental stage.10 Representative examples of them are shown in fig-
ure 8.15 
Non-nucleoside inhibitors
Nucleoside inhibitors
O
HO N N
O
NH2
CH3
OHO
O
NH2
2'-C-methylcytidine 3'-L-valine ester
O
HO OH
N
HO
N N
NH2
7-Deaza-2'-C-methyladenosine
N
N
ON
H
O
S
N
HN
HO
Benzimidazole derivative
O
O H
N
F
N
S
OH
O
O
Benzofuran derivative
 
Figure 8: Structures of potential NS5B inhibitors. 
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2.7.6 The envelope glycoproteins E1 and E2 
 
These glycoproteins form a non-covalent complex which is believed to be the building 
block for the viral envelope. Furthermore E1 and E2 are crucial for binding to human cell 
surface receptors and viral fusion.17 Therefore prevention of this binding is an attractive 
target to protect HCV target cells against infection. This approach has been demon-
strated recently by a small peptide of 14 amino acids from human CD81 large extracellu-
lar loop – with known importance in HCV-E2 binding – as well as compounds with a bis-
imidazole scaffold. Both the small peptide and the bis-imidazole derivatives (general 
structure shown in figure 9) bind to HCV-E2 preventing CD81-HCV-E2 interaction.18; 19 
 
N
HN
O
NH
R
O
X
R'
(CH2)n
X
R'
O
N NH
O
HN
R
 
Figure 9: General structure of the bis-imidazole derivatives inhibiting CD81–HCV-E2 interaction (X = N, 
O, R = amino acid ester, R’ = H, Me, Et, Bu, n = 2, 3, 4, 6). 
 
2.7.7 The internal ribosome entry site 
 
The HCV internal ribosome entry site (IRES) is essential for translation of the viral RNA 
during replication process. For this reason IRES has been considered the most attrac-
tive target for the development of RNA-based drugs. These potential inhibitors are oli-
gonucleotides like for example ISIS-14803 which consists of 20 phosphorothioate de-
oxynucleotides.20 However, development of these potential drugs was halted because of 
adverse side effects or because of limited efficacy.10; 11 
 
2.7.8 Passive or active immunization 
 
Passive immunization against HCV might be possible by the application of readymade 
antibodies whereas active immunization is achieved by administration of HCV-specific 
proteins to produce immunity to HCV. Following these two approaches led to proteins 
that are currently in preclinical or early clinical trials.14 
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2.7.9 Human receptors for HCV 
 
The most important host receptors involved in HCV binding and internalization are, 
among others, the low density lipoprotein receptor (LDLR), the very low density lipopro-
tein receptor (VLDLR), scavenger receptor class B type I (SR-BI), claudin 1, dendritic 
cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), 
liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin (L-SIGN) 
and the CD81 receptor.11 
The LDL and VLDL receptors are known to associate with HCV particles whereas their 
precise role still has to be determined. The remaining four receptors mentioned above 
are binding partners for HCV-E2 during adhesion and viral entry.11 Recently achieved 
results strengthened the possibility of potential inhibitors for the interaction of HCV with 
the mentioned host receptors in the future.18; 19; 21; 22 
 
2.8 The CD81 receptor 
 
CD81 is a member of the tetraspanin membrane protein superfamily, expressed on a 
variety of cell types, including hepatocytes. It is characterized by the presence of four 
transmembrane domains, three intracellular domains and two extracellular loops (figure 
10). In the case of CD81 the two extracellular loops are referred to as the small and 
large extracellular loops (SEL and LEL).23; 24  
 
Figure 10: Schematic illustration of the CD81 receptor. 
 
HCV-E2 binds with high affinity to the LEL of CD81 which has been demonstrated using 
recombinant HCV-E2, HCV E1-E2 complexes, HCV pseudoparticles as well as bona 
fide (from Latin: authentic, real) viral particles.17; 23; 25 Therefore CD81 is very likely to be 
involved in mediating HCV entry as an important receptor.17; 26 Whereas expression of 
Hepatocyte 
Cell membrane 
SEL 
LEL 
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CD81 in non-hepatocyte-derived cell lines not conferring susceptibility to HCV infection, 
showed that additional hepatocyte-specific factors must be required for HCV entry.11 
The role of HCV-E2–CD81 binding during HCV infection is not known yet but it is as-
sumed that this interaction may facilitate virus internalization and/or membrane fusion.19 
The elucidation of the CD81-LEL crystal structure revealed that it is a homodimer, with 
each monomer being composed of five α-helices (A to E).27 Furthermore two crystalliza-
tion structures of the LEL with particularly different folding of the head subdomain, the 
HCV-E2 binding region, are known (PDB ID 1G8Q, 1IV5) (figure 11). These different 
structures indicate a conformational flexibility, which is thought to be involved in binding 
the viral protein.27; 28  
 
 
Figure 11: Superposition of the 1G8Q (green, with pronounced cleft-like motif) and the 1IV5 (red) CD81-
LEL crystal structure with different crystal forms in the head subdomain (the identical LEL-structure is 
turquoise). 
 
Random mutagenesis was used to determine that the E2-binding site on CD81-LEL 
comprises amino acids Leu162, Ile182, Asn184 and Phe186 which are essential for vi-
rus binding. The latter three amino acids are located on the D helix of the LEL, Leu162 
occurs within a short helix located between the B and C helices.24 Furthermore the HCV-
E2 binding site on the LEL is highly conserved and therefore represents a potential tar-
get site for the development of small-molecule entry inhibitors. 
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2.9 Virtual screening approach 
 
The important structural difference of the head subdomain between the two crystal 
forms of the LEL mentioned above is caused by the C and D helices. These helices form 
a cleft-like motif (figure 11) in the case of the 1G8Q structure which does not appear in 
the 1IV5 structure. Recently this motif was used by our group in a virtual high throughput 
screening approach aiming to identify small organic molecules fitting into this cleft. The 
idea was to inhibit conformational flexibility of the receptor which makes viral entry im-
possible.29 
400.000 compounds obtained from different databases including the in-house substance 
library of our group were used for a virtual screening. Exclusion of reactive compounds 
as well as compounds which do not follow Lipinski’s Rule-of-Five resulted in approxi-
mately 100.000 compounds. These compounds were then docked into the cleft of 
1G8Q. This led to the identification of about 200 virtual hits. Compounds which were 
commercially available or accessible via an easy synthetic route were tested using the 
biological testsystem developed by Pileri et al23 for their inhibition of the CD81-LEL–
HCV-E2 interaction. As outcome of this test benzyl salicylate (figure 12) was found to be 
moderately active with an inhibition of 25 % at 50 µM. 
 
OH
O
O
 
Figure 12: Benzyl salicylate. 
 
2.10 Biological screening approach 
 
A biological screening of natural products, current drugs including several antihistamines 
and our in-house substance library (approximately 350 compounds) was performed to 
find potential small-molecule inhibitors of the CD81-LEL–HCV-E2 interaction. Biologi-
cally active compounds should serve as experimental hits to increase inhibitory potency 
by means of further structural optimization. The biological screening was performed us-
ing a medium throughput assay developed in our group.30 This test is based on an anti-
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body neutralization assay published by Pileri et al23 in which the compounds inhibit the 
binding of the fluorescence-labeled CD81 antibody JS81 to HUH7.5 cells (scheme 1). 
Inhibition of this interaction causes a decreased fluorescence compared to control cells 
without inhibitor. This was monitored by FACS measurements.  
 
 
Scheme 1: Schematic illustration of the antibody neutralization assay. 
 
This screening showed terfenadine (figure 13), an antihistamine, to be a moderate in-
hibitor of the CD81-LEL–HCV-E2 interaction (27 % at 50 µM). Other antihistamines 
showed no inhibitory activity. 
OH
(CH2)3N
OH
Ph
Ph
 
Figure 13: Terfenadine. 
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3. Aims of this work 
 
Due to the absence of a vaccine against HCV and the severe side effects of the antiviral 
drugs currently used for the treatment of chronic HCV infection there is a need for new 
potent drugs. Recent results showed the interaction of the hepatitis C virus envelope 
glycoprotein E2 (HCV-E2) with the large extracellular loop (LEL) of the human CD81 cell 
surface receptor to be essential for viral cell entry.26 The infection of human hepatocytes 
is inhibited by anti-CD81 monoclonal antibodies or by recombinant CD81-LEL.17 Fur-
thermore, compounds which bind to HCV-E2 are capable to block the CD81-LEL–HCV-
E2 interaction.19 
Our group chose the CD81-LEL as an innovative and promising target for the develop-
ment of potential inhibitors of the CD81-LEL–HCV-E2 interaction. Concerning this ap-
proach we were currently the first and are currently the only group trying to find such 
inhibitors. Furthermore the crystal structure of the LEL is available facilitating virtual 
screening methods and a cell based assay to quantify the biological activity of the pre-
pared compounds is established in our group.  
A virtual and a biological screening performed in Prof. Hartmann’s group showed benzyl 
salicylate as well as terfenadine to be moderate inhibitors of the CD81-LEL–HCV-E2 
interaction with an inhibition of 25 % (benzyl salicylate) and 27 % (terfenadine) at 50 µM.  
The aim of this thesis was the synthesis of optimized inhibitors of the CD81-LEL–HCV-
E2 interaction based on the core structures of the mentioned screening hits. Therefore, 
benzyl salicylate should be derivatized by coupling the aromatic ring containing the car-
boxyl function to variable heterocycles and by variation of the benzyl alcohol moiety. 
Additionally the benzyl alcohol moiety was intended to be substituted by amino acid es-
ters. Concerning terfenadine the aim was to structurally modify the length of the alkyl 
“linker” between the piperidine and the phenyl moiety, the alkyl substituent on the phenyl 
ring, the secondary hydroxyl group and the azacyclonol moiety. The derivatization of the 
original hit compounds was thought to increase inhibitory potency and to derive structure 
activity relationships. 
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7. Results 
 
The aim of the present work was the synthesis of potential inhibitors of the CD81-LEL–
HCV-E2 interaction. The results of this work were published in three publications out-
lined below. 
 
7.1 Structural modifications of salicylates: Inhibitors of human CD81-
receptor HCV-E2 interaction 
 
As outcome of the virtual screening procedure described in chapter 2.9 benzyl salicylate 
(figure 14) was found. Testing revealed this compound to be a moderate inhibitor of the 
CD81-LEL–HCV-E2 interaction with an inhibition of 25 % at 50 µM. 
 
OH
O
O
 
Figure 14: Benzyl salicylate (25 % inhibition at 50 µM). 
 
This was the starting point for the synthesis of benzyl salicylates with a core structure 
similar to the original hit in which the aromatic ring containing the carboxyl function 
should be coupled to variable heterocycles. Furthermore a few compounds with hetero-
cyclic substitution at the benzyl alcohol moiety were prepared. These structural modifi-
cations were performed to increase inhibition of protein-protein interaction and to im-
prove drug-likeness.  
Overall 37 compounds referring to the general structure mentioned in scheme 2 were 
synthesized by connecting substituted benzoic acids to alcohols and amines, respec-
tively. The desired esters and amides were prepared by activation of the carboxylic ac-
ids using thionyl chloride and addition of the corresponding alcohols or amines (scheme 
2). 
The carboxylic acids needed for the formation of the target compounds were prepared 
using commercially available reagents. Starting from the bromo-substituted aromatic 
heterocycle and the corresponding boronic acid Suzuki coupling was performed with 
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tetrakis-(triphenylphosphine) palladium (0) as catalyst and the desired compounds 
(scheme 2) obtained in satisfactory yields. 
 
+
Het Br
COOH COOH
(HO)2B Het
Ar
(CH2)n
YY
+ X
O
Het Y
XH
(CH2)n
Ar
 
 
Scheme 2: General structure and synthetic pathway for the preparation of the benzyl salicylates (Het = 
heterocycle, X = -O-, -NH-, Y = -H, -OH, Ar = aromat, n = 0, 1). 
 
The alcohols and amines used for the formation of the desired derivatives were com-
mercially available with the exception of the alcohol and the two amines shown in table 
1. These had to be prepared starting from the bromo-substituted heterocycle and the 
boronic acid of the corresponding alcohol or amine via Suzuki coupling, performed as 
mentioned above. 
Compound 
N
OH
 
NH2
S
 
NH2
N
 
 
Table 1: Synthesized heterocyclic substituted alcohol and amines. 
 
Biological testing of the target compounds was performed by means of the medium-
throughput assay mentioned in chapter 2.10. No synthesized compound showed an in-
crease concerning the inhibition of the CD81-LEL–HCV-E2 interaction compared to the 
original hit benzyl salicylate.  
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A possible explanation for the low activity of the compounds might be an unfavorable 
substitution pattern of the core structure that diminishes binding affinity to the LEL com-
pared to the original hit.  
 
7.2 Microwave-assisted syntheses of amino acid ester substituted 
benzoic acid amides: Potential inhibitors of human CD81-receptor 
HCV-E2 interaction 
 
The results gained in 7.1 indicated that a different substitution pattern of benzyl salicy-
late is required to increase inhibitory potency. Therefore several heterocyclic substituted 
benzoic acid amides were synthesized. The idea was to maximize more specific hydro-
gen-bonding and electrostatic interactions with the presumed binding site to increase 
inhibition.  
We decided to retain the heterocyclic substituent at the benzoic acid moiety mentioned 
in 7.1. Furthermore the benzyl ester of benzyl salicylate was replaced by amino acid es-
ters which led to 11 derivatives of the general structure shown in scheme 3. 
 
Het
AA
O
Y
+Het Br
COOH COOH
(HO)2B Het
YY
AA
 
 
Scheme 3: General structure and synthetic pathway for the preparation of the desired benzoic acid am-
ides (Het = Heterocycle, Y = -H, -OH, AA = L-alanine ethyl ester, L-phenylalanine ethyl ester, L-
tryptophane methyl ester). 
 
For the preparation of the desired benzoic acid amides microwave-assisted N, N’-
dicyclohexyl carbodiimide (DCC) coupling was used to get the compounds in satisfying 
yields. Eleven derivatives were synthesized according to the pathway given in scheme 
3. 
Before we decided to apply microwave-assisted amide syntheses, activation of the car-
boxylic acids by means of thionyl chloride followed by addition of the corresponding 
amino acid esters was tried. Since this did not lead to the desired compounds DCC cou-
pling reaction under standard conditions was performed next leading to the desired am-
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ides in very poor yields. Therefore microwave-assisted DCC coupling reaction was tried 
to increase the yield of the desired products. This attempt finally led to the target com-
pounds in satisfying yields. 
The prepared amides were tested for their inhibition of the CD81-LEL–HCV-E2 interac-
tion using the medium throughput assay mentioned in chapter 2.10. The synthesized 
benzoic acid amides showed no increased activity compared to the original hit com-
pound benzyl salicylate. 
 
7.3 Identification of terfenadine as an inhibitor of human CD81-re-
ceptor HCV-E2 interaction: Synthesis and structure optimization   
 
The biological screening mentioned in chapter 2.10 showed terfenadine (figure 15) to be 
moderately active with an inhibition of 27 % of the CD81-LEL–HCV-E2 interaction at 50 
µM. Consequently series of terfenadine derivatives were prepared to increase inhibitory 
activity and to derive structure activity relationships.  
 
OH
(CH2)3N
OH
Ph
Ph
 
 
Figure 15: Terfenadine (27 % inhibition at 50 µM). 
 
The following structural features were modified: length of the alkyl “linker” between the 
piperidine and the phenyl moiety, alkyl substituent at the phenyl ring, secondary hydroxy 
group and the azacyclonol moiety (figure 16). 
OH
(CH2)3N
OH
Ph
Ph
 
 
Figure 16: Performed derivatizations of terfenadine (coloured as mentioned in the text). 
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Concerning the derivatization of the alkyl linker length and the alkyl substituent at the 
phenyl ring a general structure and the synthetic pathway of the prepared 47 com-
pounds is shown in scheme 4. 
The desired derivatives were synthesized starting from commercially available com-
pounds. The first step of the preparation was a Friedel-Crafts (FC) acylation of the ben-
zene derivative with aluminium chloride as catalyst and the carboxylic acid chloride of 
the corresponding ω-bromo-carboxylic acid. In the next reaction step the obtained 1-aryl-
ω-bromo ketones were coupled nucleophilically to azacyclonol via microwave assisted 
syntheses leading to terfenadine precursors which were reduced using sodium boro-
hydride. This led to the corresponding terfenadine derivatives as racemates (scheme 4). 
 
Br
(CH2)n
OH
O
+
R
Br
(CH2)n
O
R
Ph
OH
Ph
NH
Ph
OH
Ph
N (CH2)n
O
R
azacyclonol
Ph
OH
Ph
N (CH2)n
OH
R  
 
Scheme 4: Synthesized terfenadine derivatives with variation of the alkyl linker length and the substituent 
at the phenyl ring (n = 3-5; R = H; C1-C4). 
 
This synthetic procedure facilitated the preparation of a large variety of compounds in a 
minimum of time since azacyclonol, the second component for the coupling reaction, 
was commercially available. 
For further modification the secondary hydroxyl group was substituted by an ester and 
an amide function. Furthermore it was reduced to the corresponding alkane. The gen-
eral structure and the synthetic pathway are shown in scheme 5. 
The exchange of the azacyclonol component by smaller piperidine moieties led to 11 
terfenadine derivatives which were synthesized via microwave assisted nucleophilic 
substitution followed by reduction of the ketone function leading to the alcohols as ra-
cemates (scheme 5). 
The piperidine of the azacyclonol moiety was exchanged by a pyrrolidine following the 
synthetic pathway mentioned in scheme 5. The prepared alcohol was obtained as race-
mate. 
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Scheme 5: Synthesized compounds: A: Amide, ester and the corresponding alkane (X = -O-, -NH-); B: 
Derivatives with small piperidine residues (R = -H, -CH3, -OH, =O, benzyl, Y = -CH2-, -O-); C: Derivatives 
with modified azacyclonol moiety. 
 
The synthesized 63 terfenadine derivatives were tested for their inhibitory potency using 
the antibody neutralization (AN) assay mentioned above (chapter 2.10). 
This showed that the alkyl substituent R (scheme 4) at the phenyl ring has a major influ-
ence on the activity. Another important feature is obviously the length of the linker, 
whereas the activities of the ketones and the corresponding alcohols did not differ sig-
nificantly. Furthermore, reduction of the ketones to the corresponding alcohols and ter-
fenadine led to a decreased activity for compounds with small substituents at the phenyl 
ring whereas a reduction of bulky substituted compounds led to derivatives with compa-
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rable inhibition. In general compounds with n = 3 showed a lower inhibition than those 
with n = 4 or 5. 
Enlargement of R from hydrogen to bulkier alkyl substituents increases inhibition. A 
maximum of inhibition, not depending on the linker length, could be reached generally 
by the use of n-propyl for the ketones and iso-butyl for the alcohols (scheme 4). The re-
duction of the ketones with R = iso-propyl to the corresponding alcohols led to a nearly 
complete loss of biological activity. The most active compound in this series of ter-
fenadine derivatives (figure 17) shows that the hexanol linker combined with an iso-butyl 
group at the phenyl ring is the most favorable substitution pattern in this class of com-
pounds. 
 
OH
(CH2)5N
OH
Ph
Ph
 
 
Figure 17: Most active compound 69 % inhibition at 50 µM. 
 
Reduction of the secondary hydroxyl group to the corresponding alkane (scheme 5) led 
to a strong decrease of inhibition. Exchange of the ketone by an ester function did not 
influence the inhibitory activity, whereas the amide group increased the inhibition. These 
SAR results indicate that the functional group X (scheme 5) might act as an H-bond ac-
ceptor interacting with the CD81 protein. 
Replacement of the azacyclonol moiety by smaller piperidine residues led to a loss of 
inhibitory activity. Substitution of the piperidine by a 4-benzyl group increased the inhibi-
tion to a moderate level (scheme 5). Again bulky substituents are essential for activity at 
this part of the molecule. 
Exchange of the piperidine of the azacyclonol moiety (scheme 5) by pyrrolidine did not 
lead to a significant change of the inhibitory activity. Obviously due to the flexibility of the 
chain, for both heterocycles appropriate conformations can be found. 
 
Selected compounds with high, moderate and low inhibition in the AN assay were tested 
for their inhibition in an infectivity assay showing that compounds with high biological 
activity in the neutralization assay showed good inhibition in the infectivity assay as well. 
This clearly indicates that inhibition of the protein-protein interaction leads to a reduction 
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of infectivity. On the other hand there are compounds which reduced infectivity without 
having been active in the AN assay. One plausible reason for this phenomenon could be 
an interaction of these compounds with an additional target which is involved in viral in-
fection. 
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8. Discussion 
 
Today, the search for new lead structures for future treatment of certain illnesses is 
based on biological experiments or on virtual screening of compound libraries. In the 
present work both approaches were used to find lead structures for the development of 
inhibitors of the CD81-LEL–HCV-E2 interaction. This interaction represents an attractive 
target for the synthesis of potential inhibitors since binding of HCV-E2 to the human 
CD81 receptor is essential for viral entry into host cells.17; 27 In more detail blocking the 
binding of HCV-E2 to CD81 by for example anti-E2 monoclonal antibodies or recombi-
nant human CD81-LEL prevents infection.17 On the other hand the CD81 receptor is not 
sufficient for viral fusion since expression on non-hepatocyte-derived cell lines does not 
facilitate infection with HCV indicating the necessity of additional hepatocyte-specific 
factors.11 
Choosing CD81-LEL as a target represents a completely new approach for the devel-
opment of potential inhibitors for the treatment of HCV infection. Pharmaceutical com-
panies follow ‘classical’ protein targets like HCV protease or polymerase. Additionally 
the LEL crystal structure and a biological test system for the potential inhibitors are 
available. Together with VanCompernolle19 and Dhanasekaran18 targeting the E2 glyco-
protein with a small peptide or organic molecules, our group is the first trying to inhibit 
the CD81-LEL–HCV-E2 interaction. 
In general prevention of protein-protein interactions is hard to realize by small molecular 
inhibitors. The challenge of such an approach is to find compounds that have sufficient 
affinity toward shallow or superficial binding sites that offer only limited chemical func-
tionalities. This stands in marked contrast to active sites or ligand binding pockets with 
high affinity to substrates and consequently to substrate analogs or other small mole-
cules.31 General reviews on this topic are given by Yin and Hamilton and Fry.32; 33 There-
fore our approach might be a ‘high risk’ but nonetheless promising advancement since 
we do not target a superficial protein-protein interaction but a cleft within the LEL as 
binding site for our compounds. This cleft is formed by two α-helices of the LEL with 
conformational flexibility which is thought to be involved in virus binding and internaliza-
tion. The synthesized molecules fitting into this cleft are thought to inhibit this conforma-
tional flexibility and therefore prevent CD81-LEL–HCV-E2 interaction (chapter 2.9). 
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With the use of both above mentioned approaches – the virtual and the biological 
screening – we maximized the possibilities to find lead structures for further structural 
optimization. As outcome of the biological screening terfenadine, an antihistamine was 
found to be a moderate inhibitor of the CD81-LEL–HCV-E2 interaction. In the course of 
this biological screening several antihistamines besides terfenadine were tested to ex-
clude the activity of terfenadine referring to antihistaminic mechanisms. Other antihista-
mines showed no inhibition. Furthermore benzyl salicylate showed a moderate inhibition 
in the virtual screening followed by biological validation as well. Both hits were structural 
modified to increase the inhibitory activity and to derive structure activity relationships. 
This led to a large variety of compounds. In the course of the derivatization the planarity 
of the original hit compounds was retained to maximize the possible interactions with the 
cleft-like region which is relatively small but quite long. 
Structural modification of benzyl salicylate did not afford compounds with an increased 
inhibitory potency. On one hand a plausible reason for this might be an unfavorable 
substitution pattern of the core structure that diminishes binding affinity to the LEL com-
pared to the original hit. On the other hand the reliability of the virtual screening methods 
is still limited but under sustained development. This makes the gained virtual results 
possibly uncertain leading to conclusions which have to be scrutinized. Otherwise the 
derivatization of terfenadine led to compounds with a clearly increased inhibitory po-
tency compared to the original hit. Furthermore the modifications of terfenadine facili-
tated significant structure activity relationships. Briefly, elongated molecules with bulky 
substituents show the highest biological activity. In addition an H-bond acceptor at the 
alkyl linker between the phenyl and the azacyclonol moiety is essential for activity. The 
most active compound within this series of terfenadine derivatives decreases the CD81-
LEL–HCV-E2 interaction by 69 % inhibition at 50 µM. This concentration is compared to 
the organic compounds prepared by VanCompernolle et al – with an inhibition of 90 % 
at 500 µM – and the small peptide developed by Dhanasekaran et al – with an inhibition 
of 50 % at 3.5 mM – a promising result. An explanation for the difference concerning the 
percental inhibition might be the differing approaches that were followed. The synthe-
sized terfenadine derivatives are thought to target the cleft-like region which appears as 
a more promising binding site for small-molecular ligands. Purely superficial regions – 
targeted by the groups of VanCompernolle and Dhanasekaran – offer only limited 
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chemical functionalities for interaction with the potential inhibitors hardening their devel-
opment and the improvement of the inhibitory potency. 
The biological activity achieved in the antibody neutralization (AN) assay was confirmed 
in an infectivity test system using viral particles. This clearly indicates that inhibition of 
the protein-protein interaction leads to a reduction of infectivity. Furthermore this test 
showed compounds to be moderate inhibitors in the infectivity assay which were not ac-
tive in the (AN) assay. One plausible reason for this phenomenon could be an interac-
tion of these compounds with an additional target which is involved in viral infection. 
Along with this, it can not be excluded that our compounds in addition also interact with 
the E2 mimicking epitope of the antibody. These possible mechanisms remain to be elu-
cidated. 
Concerning further optimization of the inhibitory potency additional structural modifica-
tions are possible. The most active compound found in this work could serve as new 
lead structure. This may facilitate further structure activity relationships and improve bio-
logical activity in which the essential structural features mentioned above should be 
kept.   
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9. Abstract / Zusammenfassung 
 
The aim of the present work was to prepare compounds which inhibit the CD81-LEL–
HCV-E2 interaction by binding to CD81-LEL.  
Starting point was a virtual screening using the open conformation of the LEL followed 
by synthesis and biological validation by means of an antibody neutralization assay.23 
This showed benzyl salicylate (figure 18) to be moderately active with an inhibition of 25 
% at 50 µM. Furthermore a biological screening revealed terfenadine (figure 18) to be a 
moderate inhibitor of the CD81-LEL–HCV-E2 interaction (27 % at 50 µM) as well. 
OH
O
O OH
(CH2)3N
OH
Ph
Ph
A B
 
Figure 18: Benzyl salicylate (A) and terfenadine (B). 
 
These two hits served as lead structures for further syntheses to increase inhibitory po-
tency. Concerning benzyl salicylate 48 compounds with diverse substitution patterns 
were prepared. The synthesized compounds showed no increased inhibitory potency 
compared to benzyl salicylate. 
For the derivatization of terfenadine 63 compounds with different structural modifications 
were synthesized. Their biological activity clearly demonstrates that a bulky substitution 
pattern at both parts of the molecule is necessary for activity as well as an H-bond ac-
ceptor at the alkyl linker. The most active compound in this series of derivatives is 
shown in figure 19. 
Additional experiments with the terfenadine derivatives using viral particles revealed that 
there might be additional HCV infection reducing mechanisms which remain to be eluci-
dated. 
OH
(CH2)5N
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Ph  
Figure 19: Most active terfenadine derivative (69 % inhibition at 50 µM). 
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Das Ziel dieser Arbeit war die Darstellung von Verbindungen, die die CD81-LEL–HCV-
E2 Interaktion durch Bindung an CD81-LEL verhindern. 
Der Ausgangspunkt hierfür war ein virtuelles Screening unter Zuhilfenahme der offenen 
Konformation der LEL, gefolgt von Synthese und biologischer Validierung mittels eines 
Antikörper-Neutralisationstests.23 Hierbei wurde Benzylsalicylat (Abbildung 20) als mä-
ßig aktive Verbindung mit einer Hemmung von 25 % bei 50 µM gefunden. Weiterhin 
zeigte ein biologisches Screening, daß Terfenadin (Abbildung 20) ebenfalls ein mäßiger 
Inhibitor (27 % bei 50 µM) der CD81-LEL–HCV-E2 Interaktion ist. 
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Abbildung 20: Benzylsalicylat (A) und Terfenadin (B). 
 
Diese beiden Hits dienten als Leitstrukturen für die weitere Synthese zur Erhöhung der 
Hemmung. Von Benzylsalicylat wurden 48 Derivate mit verschiedenartigem Substituti-
onsmuster dargestellt. Die dargestellten Verbindungen zeigten keine gesteigerte Hem-
mung im Vergleich zu Benzylsalicylat. 
Zur Derivatisierung des Terfenadin wurden 63 Verbindungen mit unterschiedlichen 
strukturellen Modifikationen hergestellt. Die biologische Aktivität dieser Verbindungen 
zeigte deutlich, daß ein voluminöser Substituent an beiden Seiten des Moleküls, sowie 
ein Wasserstoffbrückenakzeptor an dem Alkyllinker nötig sind. Die Verbindung mit dem 
höchsten Hemmwert dieser Derivate ist in Abbildung 21 dargestellt. 
Ergänzende Experimente mit viralen Partikeln zeigten, daß bei den Terfenadinderivaten 
weitere, die Infektiosität von HCV reduzierende Mechanismen eine Rolle spielen könn-
ten. Die Aufklärung dieser Mechanismen bedarf weiterer Untersuchungen.  
OH
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Abbildung 21: Aktivstes Terfenadinderivat (69 % Hemmung bei 50 µM). 
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